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Introduction
Huntington’s disease (HD) is a rare, fatal, neurodegenerative 
genetic disorder that affects muscle coordination and leads 
to behavioral symptoms and cognitive decline, resulting in 
total physical and mental deterioration over a 12- to 15-year 
period.1 HD is caused by the expansions of the polyglutamine 
(polyQ) tract in the multifunctional huntingtin protein (HTT). 
Despite the ability to identify HD mutation carriers decades 
before onset, there is currently no available therapy that can 
delay onset or slow progression of the disease.
The monogenetic etiology, autosomal dominant inheri-
tance, and the fully penetrant phenotype following a long pre-
syndromatic phase place HD as a good candidate for gene 
therapy. Consequently, there is a wide variety of potential HD 
therapeutic strategies aiming at delivery of neurotrophic fac-
tors, activation of neuronal stem cells, Ca2+ and mitochondrial 
function normalization and mutant (mt)HTT targeting.2 The 
preferred strategy by many groups including ours is direct 
lowering of the mtHTT mRNA level.
Interfering with HTT mRNA expression has been widely 
explored using synthetic antisense oligonucleotides (ASOs), 
single-stranded RNAs (ssRNAs), small interfering RNAs 
(siRNAs), expressed short hairpin RNAs (shRNAs), or arti-
ficial microRNAs (miRNAs).3–5
ASO and siRNA are chemically modified DNA or RNA oli-
gos, respectively that bind to the HTT transcript. ASO-medi-
ated HTT lowering has been successfully shown in murine 
HD models and holds a great promise for HD therapy.6,7 
Infusion of siRNAs targeting HTT into the striatum of nonhu-
man primates has demonstrated significant silencing of HTT 
in a dose-dependent manner.8 However, it still needs to be 
determined if sufficient ASO and siRNA biodistribution, effi-
cacy, and safety in the large animal and human brain can be 
achieved. Moreover, the relatively short half-life of the ASO 
and siRNA would require repeated administration presenting 
clinical burden for the HD patients.
Expressing siRNAs from shRNA or miRNA scaffolds has 
shown great promise for HTT lowering in murine HD mod-
els when delivered with adeno-associated viral (AAV) vec-
tors.4,9,10 The shRNA- or miRNA-expression can be driven by 
polymerase (pol) III or pol II promoters allowing for tissue- or 
cell-specific expression.11 Moreover, the expressed shRNA 
or miRNA provide long-term silencing of the HTT transcript, 
avoiding the necessity for readministration of the therapeutic.
Gene silencing may be indiscriminative between the wild 
type (wt) and mtHTT or can selectively silence only the 
mutated allele with expanded CAG repeats. Multiple lines 
of evidence indicate that total silencing of HTT can be per-
formed in a certain therapeutic window.12 Two studies used 
AAV2-miHTT or AAV2-shHTT to partially silence wtHTT in 
a healthy rhesus macaque putamen. In both studies, 45% 
reduction of HTT did not induce any abnormal motor phe-
notype, altered circadian behavior, fine motor skill deficits, 
neuronal loss, gliosis, or immune response at 6 weeks or 
6 months postinjection, respectively.13,14 Selective silencing 
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Huntington’s disease (HD) is a neurodegenerative disorder caused by accumulation of CAG expansions in the huntingtin (HTT) 
gene. Hence, decreasing the expression of mutated HTT (mtHTT) is the most upstream approach for treatment of HD. We have 
developed HTT gene-silencing approaches based on expression cassette-optimized artificial miRNAs (miHTTs). In the first 
approach, total silencing of wild-type and mtHTT was achieved by targeting exon 1. In the second approach, allele-specific 
silencing was induced by targeting the heterozygous single-nucleotide polymorphism (SNP) rs362331 in exon 50 or rs362307 
in exon 67 linked to mtHTT. The miHTT expression cassette was optimized by embedding anti-HTT target sequences in ten pri-
miRNA scaffolds and their HTT knockdown efficacy, allele selectivity, passenger strand activity, and processing patterns were 
analyzed in vitro. Furthermore, three scaffolds expressing miH12 targeting exon 1 were incorporated in an adeno-associated 
viral serotype 5 (AAV5) vector and their HTT knock-down efficiency and pre-miHTT processing were compared in the humanized 
transgenic Hu128/21 HD mouse model. Our data demonstrate strong allele-selective silencing of mtHTT by miSNP50 targeting 
rs362331 and total HTT silencing by miH12 both in vitro and in vivo. Ultimately, we show that HTT knock-down efficiency and 
guide strand processing can be enhanced by using different cellular pri-miRNA scaffolds.
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only of the mtHTT presents challenges as the difference 
from the wtHTT allele is mainly in the higher number of CAG 
repeats. Allele-specific HTT silencing via targeting of the 
CAG repeat is possible using ssRNAs and can be specific 
to only the mutant allele.15 Single-nucleotide polymorphism 
(SNP) genotyping of HD patients has identified ~41 SNPs 
heterozygous in at least 30% of the patients.16 Those SNPs 
are good targets for silencing of only the mtHTT while main-
taining the expression of the wtHTT allele. Allele-selective 
mtHTT silencing has been achieved with ASOs, siRNAs, 
shRNAs, or miRNAs directed toward heterozygous SNPs in 
exons 39 (rs363125), 50 (rs362331), 60 (rs2276881), or 67 
(rs362307).7,16–20
Despite the existence of many algorithms and rules for 
design of therapeutic miRNAs targeting either both HTT alleles 
or only the mutant allele based on SNPs, the evaluation of effi-
cacy and allele selectivity of every molecule still needs to be 
performed empirically. In the current study, we designed artifi-
cial miRNAs targeting human HTT exon 1 (miH), the expanded 
CAG repeats (miCAG), C or T isoform of SNP rs362331 in 
exon 50 (miSNP50C and miSNP50T) and T isoform of SNP 
rs362307 in exon 67 extended to 3’UTR (miSNP67T). miH12 
variant silenced efficiently both wt and mtHTT reporters, while 
miCAG constructs failed to induce allele-specific silencing. 
The latter was achieved by miSNP50 and miSNP67 variants 
bearing secondary mismatches to the wtHTT. Furthermore, to 
reduce the chance of off-target effects due to passenger strand 
activity, artificial miRNA processing was “biased” towards high 
concentrations of guide strand production by using different 
cellular pri-miRNA scaffolds. This resulted in differential guide 
and passenger strand processing patterns revealed by next-
generation sequencing (NGS) and HTT knockdown efficiency 
in vitro. Ultimately, to compare the HTT silencing efficiency and 
miH12 processing in vivo, three AAV5-miH12 vectors were 
generated and tested in the humanized Hu128/21 HD mouse 
model. For the first time, we show that the therapeutic pri-
miRNA scaffold influences HTT knock-down and guide strand 
processing in vivo. The best therapeutic scaffolds were miH12-
451, miSNP50C-451 and miSNP50T-451 as they induced 
strong HTT silencing and had almost undetectable passenger 
strand concentration with no activity.
Results
Huntingtin (HTT) target sequences and design of artificial 
microRNA-expression constructs
Three regions in exon 1, 50, and 67 (extended to 3’UTR) of the 
human HTT gene were selected to design artificial anti-HTT 
miRNAs (miHTTs) (Figure 1a). All miHTT variants were gen-
erated to specifically target the human HTT transcripts. The 
miHTT sequences were embedded in the engineered mmu-
pre-miR-155 scaffold (Figure 1b). The first miHTT group, 
miH1-miH21, was developed to target sequences within exon 
1, hence to induce HTT knock-down of both wt and mt alleles 
(Figure 1c). An alternative strategy aims at suppressing only 
the mtHTT allele. The majority of HD patients are heterozy-
gous for the CAG expansion and the selective targeting of 
the longer HD-associated CAG tract could potentially treat all 
patients.21 Therefore, we designed miCAG1—miCAG15 tar-
geting the CAG repeats in exon 1 to selectively suppress only 
the mtHTT allele. Recently, several SNPs have been identi-
fied in high linkage disequilibrium with the disease-associated 
allele.3,17,20,22 Notably, heterozygocity of SNP rs362307 located 
in 3’UTR of HTT (the extended exon 67) was observed in 
48.6% of US and European HD representative population 
and the T isoform of rs362307 constituted 26%. In the same 
study, heterozygocity (C/T) of SNP rs362331 located in exon 
50 was observed in 39.4%.17 In another study, heterozygoc-
ity (C/T) of rs362331 was observed in 47.6% of Italian HD 
representative population.20 Therefore, in pursuit of selective 
degradation of the mutant transcript from the HD allele, we 
selected HTT sequences that contain HD-related isoforms C 
or T of rs362331 in exon 50 and the isoform T of rs362307 
located in exon 67 (extend to 3’UTR). Consequently, we 
designed miSNP50C-1—miSNP50C-21 to silence the tran-
scripts carrying the C isoform of rs362331 (Figure 1d), 
miSNP50T-1—miSNP50T-21 to suppress the transcripts with 
the U isoform of rs362331 (Figure 1e), and miSNP67T-1 
—miSNP67T-21 to target transcripts with the U isoform of 
rs362307 (Figure 1f).
In vitro silencing efficacy of artificial miHTT constructs
To evaluate the HTT knock-down efficacy by the miHTT-
expression constructs in vitro, we cotransfected them in 
human embryonic kidney (HEK)293T cells with luciferase 
(Luc) reporters bearing complementary HTT regions fused 
to the renilla luciferase (RL) gene. Independently from RL, 
firefly luciferase (FL) was expressed from the reporter vec-
tor to correct for transfection efficiency (Figure 2a). From 
miH1-miH21 constructs designed to target both HTT alleles, 
miH10, miH14, miH15, miH19, miH20, and miH21 induced 
mild knock-down between 25–45% of LucHTT(mt) express-
ing a portion of human HTT exon 1 encompassing 73 CAG 
repeats (Figure 2b). miH12 construct was highly effective and 
induced more than 70% inhibition of LucHTT(mt) reporter.
For the allele-specific HTT suppression based on discrimi-
nating between different lengths of the CAG expansion, we 
evaluated the silencing efficacy of 15 miCAG constructs on 
Luc reporters expressing either 19 or 73 CAG repeats, named 
LucHTT(wt) and LucHTT(mt) respectively (Figure 2c). In 
contrary to previously published studies using siRNAs, ss-
siRNAs, ASOs, or different artificial miRNAs, all miCAG 
variants showed poor allele selectivity and neither of the con-
structs induced HTT knock-down stronger than 60%.15,19,23–25
Previously, several small molecules such as siRNAs, ASOs, 
shRNAs, and different artificial miRNAs targeting the isoforms 
of rs362307 or rs362331 were designed and experimentally 
tested for the allele-specific silencing of mtHTT allele.16,17,19,20 To 
estimate the ability of our miHTT constructs to induce the allele 
selectivity by owning only one nucleotide difference between 
the match and mismatch target sequences, we first cotrans-
fected miSNP50C constructs with LucSNP50C or LucSNP50T 
reporters carrying target sequences of exon 50 with either C or 
T isoform of rs362331, respectively (Figure 2d). Seven miS-
NP50C variants with the SNP-matching nucleotide at positions 
13, 14, 16, 17, 18, 20, and 21 induced mtHTT knock-down 
stronger than 70% with miSNP50C-18 being the most efficient 
and inducing ±80% knock-down of both C and T target variants. 
Neither of these constructs showed great potential to discrimi-
nate between the match and mismatch targets. Similarly to the 
www.moleculartherapy.org/mtna
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Figure 1  Design of therapeutic miHTT variants for Huntington’s disease (HD) therapy. (a) Schematic of exons 1, 50, and 67 (extended 
to 3’UTR) of human wild-type (wt) or mutated (mt) huntingtin (HTT) gene (gb|L12392.1|HUMHDA) with CAG expansions in black, target 
sequences for miH1-miH21 in yellow, miSNP50 variants in green, and miSNP67 variants in blue. Single-nucleotide polymorphisms (SNPs) 
located either in exon 50 (rs362331) or exon 67 extended to 3’UTR (rs362307) are represented as dark stripes within the target regions. 
(b) The engineered mmu-pre-miR-155 scaffold used for miHTT expression with highlighted 21 nt guide strand. (c) Twenty-one miHTT 
variants were designed to target HTT exon 1. In a consecutive manner, miH1-miH21 bind to HTT exon 1 shown in yellow with the target 
starting nucleotide positions in gray. (d) miSNP50C variants targeting the C isoform of mtHTT-associated SNP rs362331 in exon 50. Micro-
shifting of mature miSNP50C sequences along the C isoform generated 21 variants with the SNP-matching position 1–21 (miSNP50C-1—
miSNP50C-21). The C isoform is represented in dark green and the SNP-matching nucleotide in light green. (e) miSNP50T variants targeting 
the T isoform of mtHTT-associated SNP rs362331 in exon 50. miSNP50T variants were generated similarly to miSNP50C. (f) miSNP67T 
variants targeting the T isoform of mtHTT-associated SNP rs362307 in exon 67. miSNP67T variants were generated similarly to miSNP50T. 
The T isoform of rs362307 is represented in dark blue and the SNP-matching nucleotide in light blue. A list of all pre-miHTT scaffolds can be 
found in Supplementary Table S1.
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miSNP50C constructs, cotransfections of the miSNP50T con-
structs with the match LucSNP50T and mismatch LucSNP50C 
reporters showed strong HTT inhibition by a number of variants 
but overall poor allele selectivity (Figure 2e). Three miSNP50T 
variants with the SNP-matching nucleotide at positions 14, 
18, and 21 induced HTT knock-down stronger than 70% with 
Figure 2 Luciferase reporter knock-down by different miHTT variants. (a) Schematic representation of pcDNA6.2-CMV-GFP-miHTT 
constructs and luciferase (Luc) reporters. Green fluorescent protein (GFP) and miHTT variants were expressed as one transcript from the 
cytomegalovirus (CMV) promoter and the expression cassette terminated with the herpes simplex virus thymidine kinase polyadenylation (HSV 
TK polyA) signal. For the Luc reporters, sequences from HTT exon 1 with 19 or 73 CAG repeats (LucHTT(wt) or LucHTT(mt), respectively), 
exon 50 (LucSNP50C, LucSNP50T), or exon 67 (LucSNP67C, LucSNP67T) were cloned behind the renilla luciferase (RL) gene. In addition, 
firefly luciferase (FL) was coexpressed from the vector as an internal control. (b) LucHTT(mt) reporter knock-down by miH1-miH21 constructs 
targeting sequences in HTT exon 1. Human embryonic kidney (HEK)293T cells were cotransfected with 50 ng Luc reporter and 50 ng miH1-
miH21 constructs. RL and FL were measured 2 days post-transfection and RL was normalized to FL expression. Scrambled (Ctrl) served as a 
negative control and was set at 100%. (c) LucHTT(wt) and LucHTT(mt) reporter knock-down by 15 miCAG constructs targeting the CAG repeats 
of exon 1 measured 2 days post-transfection. The experimental setup is as described in (b). (d) LucSNP50 reporter knock-down by miSNP50C-
1—miSNP50C-21. LucSNP50C and LucSNP50T expressed a partial sequence of exon 50 with the isoform C or T of rs362331, respectively. 
All miSNP50C variants perfectly match to LucSNP50C and have 1 nt mismatch with LucSNP50T target sequences. HEK293T cells were 
cotransfected with 100 ng Luc reporter and 10 ng miSNP50C constructs. Luciferase expression was measured as described in (b). (e) LucSNP50 
reporter knock-down by miSNP50T-1—miSNP50T-21 constructs. All miSNP50T variants perfectly match to LucSNP50T and have 1 nt mismatch 
with LucSNP50C target sequences. Transfections and luciferase measurements were performed as described in (d). (f) LucSNP67 reporter 
knock-down by miSNP67T-1—miSNP67T-21 constructs. LucSNP67C and LucSNP67T reporters expressed a partial sequence of exon 67 with 
the isoform C or T of rs362307, respectively. All miSNP67T variants perfectly match with LucSNP67T and have 1 nt mismatch with LucSNP67C 
target sequences. Transfections and luciferase measurements were performed as in (b). The luciferase knock-down are representative figures 
of three independent experiments.
miRNA expression cassette
Luciferase reporters
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miSNP50T-18 being again the most efficient. Finally, miSNP67T 
constructs were cotransfected with the match LucSNP67T and 
mismatch LucSNP67C reporters. miSNP67T constructs with 
the SNP-matching nucleotide at position 7, 8, 9, 16, 17, and 
18 induced mild 50–60% knock-down of their match target 
and poor allele selectivity (Figure 2f). The most efficient was 
miSNP67T with the SNP-matching nucleotide at position 7 and 
showed HTT knock-down of ±60% with mild allele selectivity. 
Based on these results, miH12, miSNP50C-18, miSNP50T-18, 
and miSNP67T-7 were selected for further optimizations.
Enhancement of allele selectivity by introduction of a 
single base substitution in miSNP50C-18, miSNP50T-18, 
and miSNP67T-7 constructs
miSNP50C-18, miSNP50T-18, and miSNP67T-7 constructs 
showed good HTT silencing efficacy but poor allele selectiv-
ity in vitro. In order to enhance their potential to discriminate 
between two heterozygous HTT alleles, we introduced a sin-
gle base change at each possible position of the guide strand 
while creating the mismatch with the target sequences.26 For 
each base substitution, G or C were replaced by T, and A 
or T were replaced by C. Since the inserted guide strand 
sequences of all three variants are 21 nt long with one cru-
cial SNP-matching nucleotide, we generated 20 constructs 
for miSNP50C-18 (Figure 3a), miSNP50T-18 (Figure 3b), 
and miSNP67T-7 (Figure 3c).
To determine whether a single base substitution can 
improve the allele selectivity, we first cotransfected miS-
NP50C-18-1mm—miSNP50C-18-21mm with LucSNP50C 
or LucSNP50T reporter (Figure 3d). Each miSNP50C-
18-mm construct acquired one nucleotide mismatch with 
LucSNP50C reporter and a second nucleotide mismatch 
with LucSNP50T reporter. Overall, we observed a variation 
between miSNP50C-18-mm constructs in both the reporter 
silencing efficacy and allele discrimination. miSNP50C-
18-6mm induced mild allele selectivity and ±70% knock-down 
of the match LucSNP50C reporter. miSNP50C-18-15mm 
and miSNP50C-18-16mm showed good allele selectivity and 
match reporter knock-down stronger than 80% with miS-
NP50C-18-16mm being the most efficient.
Cotransfections of miSNP50T-18-1mm—miSNP50T-
18-21mm with LucSNP50C and LucSNP50T reporters showed 
similar trend of match reporter knock-down and allele selec-
tivity as with miSNP50C-18-mm variants, but a greater poten-
tial to discriminate between the two reporters (Figure 3e). 
miSNP50T-18-7mm and miSNP50T-18-16mm triggered good 
allele selectivity and match reporter knock-down stronger than 
80% with miSNP50T-18-7mm being the most efficient.
Cotransfections of miSNP67T-7-1mm—miSNP67T-7-21mm 
with LucSNP67C and LucSNP67T showed overall poor 
enhancement of allele selectivity and a reduction of silencing 
efficacy compared with the initial miSNP67T-7 (Figure 3f).
Generation and testing of miHTT expression vectors 
suitable for clinical use
Thus far, all miHTT variants were expressed jointly with 
green fluorescent protein (GFP) from the cytomegalovirus 
(CMV) promoter. In a vision of clinical trial preparations for 
the total HTT knock-down, we chose to optimize further the 
expression cassette of miH12. First, the CMV promoter was 
replaced by an ubiquitous CAG promoter that consisted of 
cytomegalovirus immediate-early enhancer fused to chicken 
β-actin promoter (Figure 4a). This promoter is known to 
drive stable high expression of a transgene and to be highly 
effective in the brain.27 Second, GFP was excluded from 
the expression vector to eliminate the possibility of the host 
immune response. To address the influence of the pri-miRNA 
scaffold on the processing, silencing potential of miH12 and 
the passenger strand activity, the 21 nt guide sequence 
was embedded in the human miR-1–2, miR-16-1, miR-
26a-1, miR-101-1, miR-122, miR-135b, miR-155, miR-203a, 
 miR-335, miR-451a scaffolds with 200 nt 5’ and 3’ encom-
passing flanking regions (Figure 4b). The pri-miRNA scaf-
folds were selected based on their stem-loop structure and 
the high guide versus passenger strand ratios obtained from 
miRBase release 21 (http://www.mirbase.org/). The corre-
sponding passenger strand (miH12*) was corrected in order 
to preserve the original pri-miRNA structure.
The silencing efficacy of ten CAG-miH12 expression con-
structs, named miH12-1, miH12-16, miH12-26, miH12-101, 
miH12-122, miH12-135, miH12-155, miH12-203, miH12-335, 
and miH12-451 was measured by the LucHTT(mt) knock-
down in HEK293T cells (Figure 4c). Heterogeneity in the 
silencing effect was observed for the different constructs. A 
weak 20% HTT knock-down was induced by miH12-16 scaf-
fold. miH12-101 and miH12-451 scaffolds triggered ±50% 
HTT knock-down while miH12-1, miH12-26, miH12-122, 
miH12-135, miH12-155, miH12-203, and miH12-335 scaf-
folds reached 60–70% HTT knock-down. To more precisely 
define the knock-down efficacy of the miH12 scaffolds, titra-
tion curves were generated for the best candidates  (Figure 
4d). Only at 1 ng of the transfected plasmid, we observed a 
clear difference in the LucHTT(mt) knock-down between indi-
vidual scaffolds. With 50 ng and higher concentrations of the 
plasmid, all constructs showed more than 70% LucHTT(mt) 
knock-down.
It has been shown that thermodynamic properties of 
double-stranded miRNA molecules play key roles in strand 
selection and functional assymetry.28–30 To estimate the 
silencing activity of the complementary miH12* passenger 
strand in vitro, we generated Luc reporters carrying extended 
miH12* complementary sequences (LucPassenger). 
Cotransfections of LucPassenger constructs with the corre-
sponding miH12 scaffolds in HEK293T cells showed varia-
tions in LucPassenger knock-down (Figure 4e). We detected 
no or low activity of the miH12* processed from miH12-101, 
miH12-122, miH12-135, miH12-155, and miH12-451 scaf-
folds. Strong LucPassenger knock-down was induced by the 
rest of the miH12 scaffolds.
In vitro allele-selective HTT suppression by miSNP50C 
and miSNP50T processed from miR-1, miR-101, miR-135, 
and miR-451 scaffolds
In a vision of clinical trial preparations for the allele- specific 
HTT knock-down by targeting the HD-associated SNP 
rs362331, we optimized further the expression cassette for 
miSNP50C-18-16mm (from now referred as miSNP50C) 
and miSNP50T-18-7mm (from now referred as miSNP50T). 
Based on in vitro results from ten miH12 scaffolds, we 
selected miR-1, miR-101, miR-135, and miR-451 scaffolds 
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for miSNP50C and miSNP50T. miH12-135 was highly effi-
cient and together with miH12-101 and miH12-451 did not 
produce any passenger strand. The miR-1 scaffold was 
included based on the simplicity of the stem structure. To 
evaluate their silencing and allele-selectivity potential, we 
cotransfected the different scaffolds with LucSNP50C and 
LucSNP50T reporters (Figure 5a,b). We observed a similar 
trend of match reporter knock-down and allele selectivity for 
all four scaffolds with miSNP50C-101 and miSNP50T-135 
being the most efficient. Further titrations of the miSNP50 
scaffolds revealed a concentration-dependent silenc-
ing. Representative figures of miSNP50C-451 and miS-
NP50T-451 titrations are shown (Figure 5c,d,g). Next, we 
addressed the passenger strand activity of the miSNP50C 
and miSNP50T scaffolds on LucPassenger reporters carry-
ing extended miSNP50C* and miSNP50T* complementary 
target sequences. On the contrary to our results with miH12 
constructs, we observed strong LucPassenger knock-down 
by miSNP50C* and miSNP50T* strands processed from 
miR-1, miR-101, and miR-135 scaffolds (Figure 5e,f). miR-
451 was the only scaffold that did not induce LucPassenger 
reporter silencing.
Expression of miH12 and miSNP50 from various cellular 
pri-miRNA scaffolds results in different guide and 
passenger strand processing
To demonstrate the influence of the cellular pri-miRNA scaf-
folds on miH12 and miSNP50 processing, we analyzed the 
prevalence and sequence composition of the guide and 
passenger strands by NGS. NGS was performed on small 
RNAs isolated from HEK293T cells transfected with miH12-1, 
miH12-101, miH12-122, miH12-135, miH12-155, miH12-203, 
or miH12-451 expression constructs. For miSNP50C and 
miSNP50T, we analyzed the processing from miR-135 and 
miR-451 scaffolds. For each sample, we obtained between 
15–30 mln small RNA reads that were subsequently adap-
tor-trimmed and aligned against the corresponding reference 
sequence. All reads shorter than 10 nt, longer than 45 nt, 
and represented less than 10 times were excluded from the 
analysis.
Overview of the read alignments for the different pre-miH12 
and pre-miSNP50 reference sequences is presented in 
 (Figure 6). There was a large difference in the pri-miH12 and 
pri-miSNP50 processing pattern originating from different 
scaffolds. First, miH12-101, miH12-122, miH12-155, miH12-
451, miSNP50C-451, and miSNP50T-451 scaffolds were 
processed to yield almost exclusively the guide strand with 
absent or very low concentrations of the passenger strand. 
The ratio between the guide and passenger strand was lower 
for the other miH12 scaffolds making them less attractive for 
future studies. Second, the analysis of the sequence length 
and composition of the different miH12 scaffolds revealed that 
the guide strands from all analyzed constructs were cleaved 
almost precisely at the predicted Drosha sites whereas the 
further downstream Dicer cleavage generated variability in 
the sequence length (Figure 6a). The latter ranged from 19–
31 nt depending on the scaffold. The most prevalent miH12 
length was 22 nt and originated from four scaffolds miH12-1, 
miH12-101, miH12-122, and miH12-203. Furthermore, the 
length of the most abundant read from all constructs except 
for miH12-101, miH12-155, miH12-451, miSNP50C-451, and 
miSNP50T-451 corresponded to the predicted cleavage pat-
tern obtained from miRBase release 21.
By allowing three mismatches with the reference sequence, 
we observed 3’ end sequence modifications for all the con-
structs with few that reached more than 2% threshold set 
for our analysis. This is in accordance with previously pub-
lished data on 3’end editing events in various cell lines and 
tissues.31–33 The miR-101 generated the least sequence het-
erogeneity and active passenger strand, but the most 3’end 
editing. The most abundant edited read accounted for 47.20% 
from all reads that aligned to the pre-miH12-101 reference 
sequence.
Notably, the read alignments of miH12 and miSNP50 
expressed from the miR-451 scaffold showed different length 
and cleavage patterns of the most prevalent sequences. In the 
case of miH12-451, the most abundant read (59.98%) was 
30 nt long encompassing the guide, loop and 8 nt from the 
passenger strand. The incorporated 21 nt miH12 sequence 
was detected in only 0.05% of the reads. No full-length pas-
senger strand was detected. This cleavage  pattern is typi-
cal for the non-canonical Drosha/Argonaute 2 processing 
mechanism. The read alignment analysis of miSNP50C-451 
and miSNP50T-451 revealed a completely different picture; 
for both constructs the most abundant sequences were 23 nt 
long, representing 48.52 and 42.28% of the reads matching 
the reference sequences, respectively. Similarly to miH12-
451, very little passenger strand was detected.
During miH12-135 processing, the guide strand 
sequences were generated from the 5’ arm. Interestingly, 
embedding miSNP50C and miSNP50T sequences into the 
miR-135 scaffold reversed the preference for the 5’ arm 
to serve as a guide strand and the 3’ arm as a passenger 
strand (Figure 6b).
In vivo silencing efficacy and pre-miH12 processing of 
AAV5-miH12-101, AAV5-miH12-135, and AAV5-miH12-451 
vectors
To investigate the miH12 silencing efficacy and processing 
patterns in vivo, the humanized transgenic Hu128/21 HD mice 
were injected bilaterally in the striatum with 4x1011gc per ani-
mal of AAV5 encoding miH12-101, miH12-135, miH12-451, 
or Ctrl constructs. Two months postinjection, mice were sac-
rificed and the level of HTT silencing in the brain was evalu-
ated by western blotting (Figure 7a). Similar to our in vitro 
data, miH12 induced strong more than 70% total HTT knock-
down in the striatum and more than 50% HTT knock-down in 
the cortex. Moreover, the silencing efficiency varied between 
the three scaffolds with AAV5-miH12-135 showing the stron-
gest HTT knock-down. To address the miH12 processing 
in vivo, we analyzed the prevalence and sequence composi-
tion of the guide and passenger strands by NGS. RNA was 
isolated from the cortices of Hu128/21 mice and small RNA 
NGS was performed. For each sample, we obtained between 
15–30 mln small RNA reads that were subsequently adap-
tor-trimmed and aligned against the corresponding reference 
sequence. All reads shorter than 10 nt, longer than 45 nt, 
and represented less than 10 times were excluded from the 
analysis. Overview of the read alignments for pre-miH12-135 
and pre-miH12-451 scaffolds is represented in (Figure 7b). 
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Figure 3 Introduction of a mismatch to miSNP50C-18, miSNP50T-18, and miSNP67T-7 to improve mtHTT allele selectivity. (a) Twenty 
variants named miSNP50C-18-1mm to miSNP50C-18-21mm were generated with one mismatch to the C-target sequence at positions 1–21 
and two mismatches to the T-target sequence: one at position 18 and the other at positions 1–21. In all variants, G or C were replaced by T, and 
A or T by C. The C isoform of rs362331 is represented in dark green, the SNP-matching nucleotide in light green and the mismatch in grey. (b) 
Twenty variants named miSNP50T-18-1mm—miSNP50T-18-21mm were designed as described in (a). (c) Twenty variants named miSNP67T-
7-1mm—miSNP67T-7-21mm were designed as described in (a). The T isoform of rs362307 is represented in dark blue, the SNP-matching 
nucleotide in light blue and the mismatch in dark gray. (d) LucSNP50 reporter knock-down by miSNP50C-18-1mm to miSNP50C-18-21mm 
constructs. Human embryonic kidney (HEK)293T cells were cotransfected with 50 ng Luc reporter and 50 ng miSNP50C-18 constructs. Renilla 
(RL) and firefly (FL) luciferases were measured 2 days post-transfection and RL was normalized to FL expression. Scrambled (Ctrl) served 
as a negative control and was set at 100%. (e) LucSNP50 reporter knock-down by miSNP50T-18-1mm to miSNP50T-18-21mm constructs. 
Transfections and luciferase measurements were performed as described in (d). (f) LucSNP67 reporter knock-down by miSNP67T-7-1mm—
miSNP67T-7-21mm constructs. HEK293T cells were co-transfected with 30 ng Luc reporter and 3 ng miSNP67T constructs. Luciferase 
expression was measured as in (d). The miSNP50C-18-16mm and miSNP50T-18-7mm constructs selected for further optimization are 




















































13 14 15 16 17 19 20 21 Ctrl 1 2 3 4 5 6 7 8 9 10 11 12
miSNP50T-18-mm
13 14 15 16 17 19 20 21
Ctrl 1 2 3 4 5 6 8 9 10 11 12
miSNP67T-7-mm










































































































































Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington’s Disease
Miniarikova et al.
8
Figure 4 Optimization of the miH12 expression cassette to address efficacy and passenger strand activity. (a) Schematic 
representation of the pri-miH12 expression cassette with the CMV immediate-early enhancer fused to chicken β-actin (CAG) promoter and 
human growth hormone polyadenylation (hGH polyA) signal. (b) Ten cellular pri-miRNA scaffolds were selected from miRBase database 
(www.mirbase.org) based on the guide/passenger strand prevalence and RNA folding. Twenty-one nt of the guide strand were replaced by the 
mature miH12 sequence and the passenger strand was corrected in order to preserve pri-miH12 scaffolding. Based on miRBase, the predicted 
guide and passenger strand sequences of the cellular pre-miRNA scaffolds are indicated in red and blue, respectively. (c) LucHTT(mt) reporter 
knock-down by ten miH12 scaffolds. Human embryonic kidney (HEK)293T cells were cotransfected with 100 ng LucHTT(mt) reporter and 10 ng 
miH12 constructs. Renilla (RL) and firefly (FL) luciferases were measured 2 days post-transfection and RL was normalized to FL expression. 
Scrambled (Ctrl) served as a negative control and was set at 100%. (d) Titration curve of miH12 embedded in the human miR-1, miR-101, miR-
122, miR-135, miR-203, and miR-451 scaffolds. HEK293T cells were cotransfected with 50 ng LucHTT(mt) reporter and 1, 10, 50, 100, or 250 
ng of miH12 constructs. Luciferase expression was measured as described in (c). (e) In vitro passenger strand activity of miH12-1, miH12-26, 
miH12-101, miH12-122, miH12-135, miH12-155, miH12-203, miH12-335, and miH12-451 scaffolds. For the LucPassenger reporters, reverse 
complement sequences to the miH12 passenger strand sequences were cloned behind RL. In addition, FL was coexpressed from the vector 
as an internal control. Transfections and luciferase measurements were performed as in (c). The luciferase knock-down are representative 
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In the case of miH12-451, the most abundant reads were 
30 nt and 23 nt long, respectively. In case of miH12-135, 
we observed similar Dicer cleavage pattern as we observed 
in vitro. Surprisingly, the most abundant read was 19 nt long 
and accounted for 33.51%. We also observed similar 3’end 
editing events from both scaffolds compared to our in vitro 
data.
Our results demonstrate that the incorporation of identical 
sequences in various pri-miRNA scaffolds results in different 
HTT knock-down and processing of guide and passenger 
strands both in vitro and in vivo. As a consequence, every 
scaffold yielded its own “fingerprint” of mature miH12 and 
miSNP50 sequences. Based on the silencing efficacy and pro-
cessing profile, we selected miH12-451 for further development 
as the artificial miRNA-based therapeutic candidate for HD.
Discussion
Given the complexity of pathology and natural history of HD, 
HTT transcript lowering approaches come to focus since they 
aim to reduce the concentration of the malfunctioned protein. 
To date, both total and allele-specific HTT down-regulation 
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strategies are moving forward to the clinic. siRNAs and ASOs 
show positive results when targeting either both alleles or 
only mtHTT allele in vitro and in vivo.7,15,16,34,35 However, the 
periodical readministration of these therapeutics is required 
which adds more risk for infections and burden on the patients. 
Recently, the artificial RNAi-based approach using shRNAs 
or miRNAs has been proposed for the sustained total and 
allele-selective HTT down-regulation.10,13,18,19 In general, shR-
NAs are expressed from pol III promoters and miRNAs from 
pol II promoters. Evidence suggests that expressing artificial 
shRNAs from strong pol III promoters can induce severe tox-
icity at high doses.36–38 In some cases, the toxicity correlates 
with high production of the passenger strand, independent 
from the target HTT mRNA inhibition.39 Importantly, switch-
ing to miRNA-based expression system can reduce the toxic 
effect.36 Thus, a promising approach for the HD therapy is 
considered the pol II expression of artificial miRNAs target-
ing HTT transcripts delivered with viral vectors. Nevertheless, 
a detailed analysis on miRNA processing patterns, such as 
sequence composition, guide/passenger strand ratios, and 
passenger strand activity is necessary to estimate the poten-
tial cellular toxicity in vivo.
In the current study, we have evaluated three different 
approaches for HTT silencing using expressed artificial 
miHTTs. Total HTT knock-down was induced by targeting 
both wtHTT and mtHTT alleles with miH1-miH21 directed 
towards exon 1. The feasibility of the allele-specific silenc-
ing was evaluated by targeting the CAG repeats or hetero-
zygous SNPs rs362331 and rs362307 in the HTT gene. 
Construct optimization of the best miH12, miSNP50C, and 
miSNP50T candidates has been performed by introduction 
of single base substitutions in the guide strand sequences, 
adapting the expression cassette and using different cellular 
pri-miRNA scaffolds. The silencing efficacy, allele selectivity, 
analysis of miH12, miSNP50C, and miSNP50T processing 
patterns, and evaluation of the passenger strand activity sup-
ported the selection of the best therapeutic candidate for fur-
ther development.
Several lines of investigation suggest that sufficient inhibi-
tion of mtHTT while maintaining wtHTT at adequate levels is 
achievable and therapeutically beneficial.8,10,13,40 For instance, 
lentiviral delivery of shRNAs targeting both HTT alleles 
reduced HD-like neuropathology in the HD rat model.10 In 
another study with the transgenic HD mice, more than 70% 
total HTT knock-down using artificial miRNAs was efficacious 
with no apparent toxicity 3 months postinjection.40 The safety 
of the nonallele-selective HTT approach was also evaluated 
in nonhuman primates where it showed tolerance to 45% 
HTT knock-down.8,13 Additionally, from the drug manufactur-
ing perspective, single product development and drug avail-
ability for all HD-allele carriers favor nonallele-selective HD 
approaches forward to the clinic. Here, we identified miH12, 
which induced more than 70% HTT knock-down both in vitro 
and in vivo as the therapeutic candidate for further develop-
ment. Also, we optimized the expression cassette of miH12 
to make the vector suitable for clinical use.
Despite the promising results for the total HTT knock-
down, the model therapy would inhibit only the mtHTT allele 
while preserving wtHTT at normal levels. To achieve this, we 
initially designed 15 miCAG constructs with either perfect 
or partial complementarity to the CAG repeats. It has been 
shown that introducing base changes at a specific position 
within siRNA sequences that target CAG repeats enhanced 
HD allele discrimination.23 We applied this knowledge when 
generating our miCAG constructs. However, none of the con-
structs induced good allele selectivity. Recently, ASOs and 
miRNAs perfectly complementary to CAG repeats with one 
mismatch at position 9 showed good allele selectivity.39,41 Dif-
ferences in the mismatch position, base composition, and 
expression cassette could explain the contrast in allele selec-
tivity between theirs and our CAG-targeting constructs.
To design allele-specific HD therapy by targeting the 
mtHTT allele-linked SNPs, ideally, HD patients would be het-
erozygous for a specific SNP with one isoform linked to the 
mtHTT. However till now, no such SNP has been discovered. 
Evidence shows that a combination of targetable isoforms 
originating from different SNPs will be required to treat the 
majority of HD population.17 Very similarly to miCAG con-
structs, artificial miRNAs designed to target the HD-linked 
isoform T of rs362307 could not discriminate well between the 
two heterozygous alleles. Similar results have been shown 
in rodent HD models using siRNAs, shRNAs and different 
artificial miRNAs.17–19 Moreover, the introduction of second-
ary mismatches did not improve the allele specificity in vitro. 
Figure 5 Optimization of the miSNP50C and miSNP50T expression cassette to address efficacy and passenger strand activity. 
(a) LucSNP50 reporter knock-down by four different pri-miSNP50C scaffolds. Twenty-one nt mature miSNP50C-18-16mm sequence, from now 
referred as miSNP50C, was embedded as a guide strand in the human miR-1, miR-101, miR-135, and miR-451 scaffolds and the passenger 
strand was corrected in order to preserve pri-miSNP50C folding. Human embryonic kidney (HEK)293T cells were cotransfected with 50 ng 
luciferase (Luc) reporter and 10 ng miSNP50C constructs. Renilla (RL) and firefly (FL) luciferases were measured 2 days post-transfection and 
RL was normalized to FL expression. Scrambled (Ctrl) served as a negative control and was set at 100%. (b) LucSNP50 reporter knock-down by 
four different pri-miSNP50T constructs. Twenty-one nt mature miSNP50T-18-7mm sequence, from now referred as miSNP50T, was embedded 
as a guide strand in the human miR-1, miR-101, miR-135, and miR-451 scaffolds and the passenger strand was corrected in order to preserve 
pri-miSNP50T folding. HEK293T cells were co-transfected with 50 ng Luc reporter and 10 ng pri-miSNP50T constructs. Luciferase expression 
was measured as in (a). (c) Titration curve of miSNP50C embedded in the miR-451 scaffold, from now referred as miSNP50C-451. HEK293T 
cells were cotransfected with 25 ng Luc reporter and 0.5, 5, 25, 50, or 125 ng of miSNP50C-451 construct. Luciferase expression was measured 
as described in (a). (d) Titration curve of miSNP50T embedded in the miR-451 scaffold, from now referred as miSNP50T-451. Transfections 
and luciferase measurements were performed as in (c). (e) In vitro passenger strand activity of miSNP50C embedded in the miR-1, miR-101, 
miR-135, and miR-451 scaffolds. For the LucPassenger reporters, reverse complement sequences to the four miSNP50C passenger strand 
sequences were cloned behind RL. In addition, FL was coexpressed from the vector as an internal control. HEK293T cells were cotransfected 
with 25 ng Luc reporter and 5 ng miSNP50C constructs. Luciferase measurements were performed as in (a). (f) In vitro passenger strand activity 
of miSNP50T embedded in the miR-1, miR-101, miR-135, and miR-451 scaffolds. Transfections and luciferase measurements were performed 
as in (e). (g) Allele selectivity ratios of miSNP50C and miSNP50T embedded in the miR-1, miR-101, miR-135, and miR-451 scaffolds. IC50 
indicates a concentration (ng) of miSNP50 construct that is required for 50% Luc reporter knock-down. LucSNP50C represents a match reporter 
for miSNP50C constructs and a mismatch reporter for miSNP50T constructs, and vice versa. The allele selectivity ratios were calculated as 
IC50(mismatch)/IC50(match). The luciferase knock-down are representative figures of two independent experiments.
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In contrast, previously it has been shown that some siRNAs 
targeting the isoform T of rs362307 and carrying a secondary 
mismatch to the wtHTT allele, showed good allele selectivity, 
which might be due to differences in the effective therapeutic 
sequence, administration, test system, and concentration.17
A great portion of the Caucasian HD population is hetero-
zygous (C/T) for rs362331 in exon 50.3 Here, we designed 42 
different artificial miSNP50 by micro-shifting the 21 nt guide 
strand along the HTT target sequence that contained either 
C or T isoform of rs362331. In contrary to previously pub-
lished data with shRNAs and siRNAs, none of the constructs 
induced immediate good allele selectivity.18,20 Very likely, 
the length of the guide strand, sequence composition and 
miRNA processing contributed to the observed differences. 
The allele selectivity was achieved after introducing single 
nucleotide substitutions at specific positions within the guide 
strand, as previously suggested.26
In the canonical processing pathway, cellular miRNAs are 
expressed from the genome mainly by RNA pol II as long 
pri-miRNAs.42 The pri-miRNA transcripts fold into specific 
stem-containing RNA scaffolds which determinate their fur-
ther processing by the Microprocessor complex.43–45 Further 
downstream, Dicer cleaves the loop-containing precursor into 
a mature double-stranded miRNA structure composed of the 
more active guide strand and its complementary passenger 
strand.46 The main concerns when using artificial miRNAs 
are the off-target effects and saturation of RNAi machinery 
caused by events linked to cellular processing of mature 
miRNA strands and target similarity with other genes.38,39,47 
Here, for the first time, we evaluated the efficacy and pro-
cessing of miH12, miSNP50C, and miSNP50T from several 
pri-miRNA scaffolds for a single HD therapeutic. We have 
performed detailed NGS analysis of the artificial miRNA pro-
cessing and the passenger strand activity both in vitro and in 
vivo, which varied depending on the scaffold. Moreover, we 
showed that embedding miH12, miSNP50C, and miSNP50T 
sequences in the same miR-135 scaffold resulted in differ-
ent cellular processing of guide and passenger strands. For 
instance, cellular processing of miH12-135 favored produc-
tion of the 5’arm over the 3’arm. However, miSNP50C-135 
and miSNP50T-135 processing had reversed preferences, 
the 3’arm served as the predominant guide strand. Variabil-
ity in the miRNA scaffold, thermodynamic properties of the 
duplex miRNA, 3’overhangs of the both strands could result 
in the observed differences.
In the noncanonical pathway, the pre-miR-451 escapes 
Dicer cleavage and only a 5’ arm strand is active on the tar-
gets.48,49 The mature guide strand sequence of the miR-451 
is generated by cleaving the 3’arm between 10–11 nt from 
the stem origin which yields a 30 nt long intermediate that 
is subsequently trimmed by poly(a)-specific ribonuclease 
(PARN) into a mature ~23 nt long active molecule.50–52 Inter-
estingly, NGS on miH12-451 processing in vitro showed a 
30 nt long predominant read, but for miSNP50C-451 or 
miSNP50T-451 the read was only 23 nt long. Moreover, 
miH12-451 processing in vivo showed equal ratios of the 
30 nt and 23 nt long molecules. It has been reported that 
PARN-associated trimming exhibit nucleotide preferences at 
the 3’end of AGO2-cleaved intermediates and is not required 
for target silencing.52 Construct concentration and the cellular 
environment could be potential reasons for the lack of a ~23 
nt long active miH12 molecules in vitro.
Ultimately, our NGS analysis showed 3’end miRNA edit-
ing events both in vitro and in vivo. In both cases, adenos-
ine or uracil was added to the mature guide sequences. This 
resulted in a formation of several mature miH12 isoforms 
containing the same seed region. Previous studies report 
that trimming and tailing influence the stability and process-
ing of pre- miRNAs, mature miRNAs or mRNA sequences.53–56 
However, the exact roles of miH12 mono-uridylation and 
mono-adenylation still needs to be determined.
Altogether, our results highlight the necessity of careful 
selection and characterization of the therapeutic product 
both in vitro and in vivo before entering the clinic. A number 
of parameters need to be carefully evaluated including gene 
silencing efficacy, miRNA processing pattern, and induction 
of off-target effects.
Materials and methods
HTT target sequences. Homo sapiens HD mRNA, complete 
cds (gb|L12392.1|HUMHDA) obtained from http://blast.ncbi.
nlm.nih.gov/Blast.cgi was used to identify target sequences 
for the artificial miHTTs. miH1-21 targeted sequences in 
exon 1 (pos.185–579), miCAG constructs targeted the CAG 
repeats (pos.367–429), miSNP50 constructs targeted SNP 
rs362331 (pos.7246), and miSNP67 constructs targeted 
SNP rs362307 (pos.9809).
DNA constructs. To create the miHTT vectors, miRNA 
sequences targeting HTT transcripts were embedded 
into the murine pre-miR-155 backbone of pcDNA6.2-
GW/EmGFP-miR (Invitrogen, Carlsbad, CA) by anneal-
ing complementary oligonucleotides (Qiagen, Valencia, 
CA) and ligation into the linearized pcDNA6.2 plas-
mid. As a negative control, pcDNA6.2-GW/EmGFP- 
miR-neg control (Invitrogen) was used, named Ctrl. miH12 
and miSNP50 sequences were subsequently incorporated 
in cellular pri-miRNA scaffolds of the human miR-1–2, miR-
16-1, miR-26a-1, miR-101-1, miR-122, miR-135b, miR-155, 
miR-203a, miR-335, and miR-451a. 200 nt 5’ and 3’ flanking 
Figure 6 Next-generation sequencing (NGS) analysis on the processing of miH12-1, miH12-101, miH12-122, miH12-135, miH12-155, 
miH12-203, miH12-451, miSNP50C-135, miSNP50T-135, miSNP50C-451, and miSNP50T-451 scaffolds. (a) Sequence distribution (%) 
of reads mapping to miH12-1, miH12-101, miH12-122, miH12-135, miH12-155, miH12-203, miH12-451, miSNP50C-135, miSNP50T-135, 
miSNP50C-451, and miSNP50T-451 pre-miRNA scaffold sequences. Human embryonic kidney (HEK)293T cells were transfected with 
4 μg of the constructs, 48 hours post-transfection RNA was isolated and small RNA NGS was performed. For each variant, the miHTT 
scaffold is shown in the first column. Based on miRBase, the predicted guide and passenger strand sequences of the cellular pri-miRNA 
scaffolds are indicated in red and blue, respectively, 5’ and 3’ flanking nucleotides in black, and a mismatch with the reference sequence 
in green. (b) Length distribution of reads mapping to miH12-1, miH12-101, miH12-122, miH12-135, miH12-155, miH12-203, miH12-451, 
miSNP50C-135, miSNP50T-135, miSNP50C-451, and miSNP50T-451 scaffold sequences. For the read alignments, up to three mismatches 
with the references sequences were allowed. Reads represented with less than 2% were excluded from the figure.
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regions were included with EcoRV and BamHI restriction 
sites and the complete sequences were ordered from 
GeneArt gene synthesis (Invitrogen). In those constructs, the 
CMV promoter was replaced by the CMV immediate-early 
enhancer fused to chicken β-actin (CAG) promoter (Inovio, 
Plymouth Meeting, PA).
For generation of the luciferase reporters LucHTT(wt) or 
LucHTT(mt), HTT exon 1 containing 19 or 73 CAG repeats 
respectively was linked to 83 nt from HTT exon 67 contain-
ing C/T at SNP rs362307 (pos.9809) and the fragment was 
cloned in the 3’UTR of the RL gene of the psiCHECK-2 vec-
tor (Promega, Madison, WI). For generation of LucSNP50C 
and LucSNP50T constructs, 48 nt fragment from HTT exon 
50 containing C/T at SNP rs362331 (pos.7246) was cloned 
in the 3’UTR of the RL gene of the psiCHECK-2 vector 
(Promega). For different LucPassenger reporters, reverse 
complements of the passenger strands with 5 nt added from 
the Dicer cleavage sites were generated by CLC Main Work-
bench (version 6.6.1) and ordered (Qiagen). Annealed com-
plementary oligonucleotides were cloned in the 3’UTR of the 
psiCHECK-2 vector (Promega). The mfold program (http://
mfold.rna.albany.edu/?q=mfold) was used to determine 
the secondary structure of the RNA transcripts. The mfold 
structures of the oligonucleotides used in this study are listed 
in Supplementary Table S1.
Cell culture and transfections. The human embryonic kid-
ney (HEK)293T cells were maintained in Dulbecco’s modi-
fied Eagle’s medium (Invitrogen) containing 10% fetal calf 
serum (Greiner, Kremsmünster, Austria), 100 U/ml penicillin 
and 100 U/ml streptomycin (Thermo Fisher, Waltham, MA), 
at 37 °C and 5% CO
2. For luciferase assays and small RNA 
NGS, cells were seeded in 24- or 6-well plates at a density 
of 1.2*105 or 0.5*105 cells per well, respectively, in Dulbec-
co’s modified Eagle’s medium (Invitrogen) 1 day prior trans-
fection. Transfections were performed with Lipofectamine 
2000 reagent (Invitrogen) according to the manufacturer’s 
instructions.
Luciferase assays. HEK293T cells were cotransfected with 
miHTT expression constructs and luciferase reporters that 
contain both the RL gene fused to miHTT target sequences 
and the FL gene. Transfected cells were assayed at 48 hours 
post-transfection in 100 μl 1× passive lysis buffer (Promega) 
by gentle rocking for 15 minutes at room temperature. The 
cell lysates were centrifuged for 5 minutes at 4,000 rpm and 
Figure 7 HTT knock-down by AAV5-miH12-101, AAV5-miH12-135, AAV5-miH12-451 vectors and next-generation sequencing (NGS) 
analysis on miH12 processing in the humanized Hu128/21 HD mouse model. (a) Top, an example western blot showing wtHTT and mtHTT 
knock-down by AAV5-miH12-101, AAV5-miH12-135, and AAV5-miH12-451 viruses. Bottom, quantification of HTT protein in the striata and cortices 
of Hu128/21 mice 2 months postinjection with AAV5-miH12-101, AAV5-miH12-135 and AAV5-miH12-451 viruses. Density of HTT bands was 
normalized to β-tubulin loading control and shown as a percentage of the same allele (either wtHTT or mtHTT) from Ctrl animals. (b) Sequence 
distribution (%) of reads mapping to miH12-135 and miH12-451 scaffolds. Cortices were isolated from mice 2 months postinjection of AAV5-
miH12-135 and AAV5-miH12-451. RNA was isolated from tissue homogenate and small RNA NGS was performed. For each variant, the miHTT 
scaffold is shown on top. First two most abundant sequences are represented by the arrow. For the read alignments, up to three mismatches with 
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10 μl of the supernatant was used to measure FL and RL 
activities with the Dual-Luciferase Reporter Assay System 
(Promega). Relative luciferase activity was calculated as the 
ratio between RL and FL activities. Allele selectivity ratio of 
the miSNP50 and miSNP67 variants was calculated on the 
IC50 given as the concentration in (ng) of miSNP needed to 
reach the half-maximal inhibition and dividing the IC50 of the 
mismatch reporter against the IC50 of the match reporter.
RNA isolation and next-generation sequencing (NGS). 
HEK293T cells were transfected with 4 μg miH12 and 
miSNP50 expression plasmids using Lipofectamine 2000 
reagent (Invitrogen) and total RNA was isolated from cells 48 
hours post-transfection using Trizol (Invitrogen) according to 
the manufacturer’s protocol. Cortices isolated from Hu128/21 
mice were tissue homogenized in Trizol (Invitrogen) using 
gentleMACS Dissociator (Miltenyi Biotec, Bergisch Glad-
bach, Germany) and total RNA was isolated from Trizol 
according to the manufacturer’s protocol (Invitrogen). Small 
RNA sequencing libraries for the Illumina sequencing plat-
form were generated using high-quality total RNA as input 
and the NEXTflex Small RNA Sequencing kit (Bioo Scientific, 
Austin, TX). Briefly, the small RNA species were subjected to 
ligation with 3’ and 5’ RNA adapters, first strand reverse tran-
scription, and polymerase chain reaction (PCR) amplification. 
Sample-specific barcodes were introduced in the PCR step. 
The PCR products were separated on TBE-PAGE electro-
phoresis and the expected band around 30 bp was recovered 
for each sample. The resulting sequencing libraries were 
quantified on a BioAnalyzer (Agilent, Santa Clara, CA). The 
libraries were multiplexed, clustered, and sequenced on an 
Illumina HiSeq 2000 (TruSeq v3 chemistry) with a single-read 
36 cycles sequencing protocol and indexing. The sequencing 
run was analyzed with the Illumina CASAVA pipeline (v1.8.2), 
with demultiplexing based on sample-specific barcodes. The 
raw sequencing data produced was processed removing the 
sequence reads which were of too low quality (only “passing 
filter” reads were selected). In total, we generated between 
15–35 mln reads per sample.
NGS data analysis. NGS small RNA raw data sets were ana-
lyzed using the CLC Genomics Workbench 6 (Qiagen). The 
obtained reads were adaptor-trimmed, which decreased the 
average read size from ~50 bp to ~25 bp. The custom adapter 
sequenced used for trimming all the bases extending 5’ was: 
GTGACTGGAGTTCCTTGGCACCCGAGAATTCCA.  All reads 
containing ambiguity N symbols, reads shorter than 10 nt, 
longer than 45 nt, and reads represented less than 10 times 
were discarded. Next, the obtained unique small RNA reads 
were aligned to the references sequences of the  pre-miHTT 
constructs (Supplementary Table S1) with a max. of 3 nt 
mismatches allowed. The percentages of reads based on the 
total number of reads matching the reference sequence were 
calculated.
AAV5 vector production. AAV5 vectors encoding miH12 and 
Ctrl were produced by a baculovirus-based AAV production 
system. Briefly, the miRNA constructs were synthesized and 
cloned in an expression vector containing the CAG promo-
tor. The CAG-miRNA cassette was obtained by digestion 
with restriction enzymes HindIII and PvuI and cloned in a 
uniQure transfer plasmid named pVD789 in order to gener-
ate an entry plasmid. The presence of the two inverted ter-
minal repeats (ITRs) was confirmed by restriction digestion 
with SmaI. The ITR-CAG-miRNA cassette was inserted in 
a recombinant baculovirus vector (Bac.AMT5) by homolo-
gous recombination in Sf9 cells and clones were selected by 
plague purification. The recombinant baculovirus containing 
the ITR-CAG-miRNA were further amplified till P6 in Sf+ cells 
and screened for the best production and stability by PCR 
and qPCR. To generate AAV5, Sf+ cells were triple infected 
with three different recombinant baculoviruses expressing 
the ITRs-CAG-miRNA, the replicon enzyme (rep 183) and 
the capsid protein (cap 765). The cells were lysed 72 hours 
after the triple infection and the crude lysate was treated 
with Benzonase (50U/ml) (Merck, Darmstadt, Germany) for 
1 hour at 37 °C. AAV5 was purified on an AVB Sepharose 
column (GE Healthcare, Little Chalfont, UK) using an AKTA 
purification system (GE Healthcare) and the final concentra-
tion was determined by quantitative PCR with primers ampli-
fying a 95bp fragment from the CAG promoter region. The 
final product was sequence verified by NGS.
Mice and treatments. Humanized transgenic HD mice 
expressing full-length genomic human mtHTT from the 
YAC128 transgene and full-length genomic human wtHTT 
from the BACWT transgene (Hu128/21, Amber L South-
well, the manuscript in preparation) were maintained under 
a 12-hour light: 12-hour dark cycle in a clean facility with free 
access to food and water. Experiments were performed with 
the approval of the animal care committee at the University 
of British Columbia. Two-month-old animals were injected 
bilaterally with AAV5-miRNAs as in ref. 57. Briefly, mice were 
anesthetized with isoflurane, placed into a stereotaxic frame, 
and the scalp prepared. An incision was made along the mid-
line and burr holes drilled in both hemispheres of the skull at 
0.8 mm anterior and 1.8 mm lateral to Bregma. A 5 μl Hamil-
ton syringe loaded with 3 μl of sterile saline and 2 μl of viral 
solution (such that the viral solution would be injected first 
followed by the saline) was then lowered to mid striatum at 
a depth of 3.5 mm and the full 5 μl was injected at a rate of 
0.5 μl/minute. The needle was left in place for additional 5 
minutes and withdrawn slowly.
HTT immunoblotting. Two months after treatment, mice were 
killed with an overdose of avertin followed by cervical disloca-
tion. Brains were removed, briefly placed on ice to increase 
tissue rigidity, and microdissected by region. Striata and cor-
tices were equilibrated in RNAlater solution (Ambion) over-
night at 4 °C before storage at −80 °C. Allelic HTT protein 
was then quantified in the striatum and cortex of three ani-
mals per condition by immunoblot as in ref. 16. Briefly, tis-
sue was lysed in single detergent lysis buffer, total protein 
quantified by DC assay (Bio-Rad, Hercules, CA), and 40 μg 
total protein resolved on 10% low-bis acrylamide gels (200:1 
acrylamide:bis). Proteins were transferred to 0.45 μm nitro-
cellulose membranes, which were probed for HTT (MAB2166 
1:2,000, Millipore, Billerica, MA) and β-tubulin loading con-
trol (1:5,000, Sigma-Aldrich, St. Louis, MO). Secondary IR 
dye 800CW goat anti-mouse (1:250, Rockland, Limerick, PA) 
www.moleculartherapy.org/mtna
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antibody and the LiCor Odyssey infrared imaging system 
were used to visualize proteins. The intensity of each allele of 
HTT was normalized to β-tubulin and then to the mean value 
for the same allele from Ctrl injected animals on the same 
membrane.
Supplementary material
Table S1. The mfold scaffolds of pre-miRNA sequences 
used in the study.
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